NEW YORK (GenomeWeb) – Synthetic Genomics and Gen9 today announced a licensing deal. 

The agreement provides Gen9 a non-exclusive worldwide license to SGI's Febit intellectual property estate. The technology, purchased in 2012 by SGI from Febit Holding, comprises three families of patents and patent applications covering synthetic genomic methods. They include methods for highly parallelized, low-cost oligonucleotide synthesis and retrieval of sequence-validated DNA. SGI has been using the technology to develop gene synthesis applications. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.